Cargando…

Effects of rifampin, itraconazole and esomeprazole on the pharmacokinetics of alisertib, an investigational aurora a kinase inhibitor in patients with advanced malignancies

Aim Two studies investigated the effect of gastric acid reducing agents and strong inducers/inhibitors of CYP3A4 on the pharmacokinetics of alisertib, an investigational Aurora A kinase inhibitor, in patients with advanced malignancies. Methods In Study 1, patients received single doses of alisertib...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Xiaofei, Pant, Shubham, Nemunaitis, John, Craig Lockhart, A., Falchook, Gerald, Bauer, Todd M., Patel, Manish, Sarantopoulos, John, Bargfrede, Michael, Muehler, Andreas, Rangachari, Lakshmi, Zhang, Bin, Venkatakrishnan, Karthik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2017
Materias:	Phase I Studies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5869871/ https://www.ncbi.nlm.nih.gov/pubmed/28852909 http://dx.doi.org/10.1007/s10637-017-0499-z

Ejemplares similares

Effect of alisertib, an investigational aurora a kinase inhibitor on the QTc interval in patients with advanced malignancies
por: Zhou, Xiaofei, et al.
Publicado: (2017)

Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors
por: Falchook, Gerald S., et al.
Publicado: (2015)

Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib
por: Steeghs, Neeltje, et al.
Publicado: (2010)

Phase I study assessing the mass balance, pharmacokinetics, and excretion of [(14)C]-pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors
por: Zhou, Xiaofei, et al.
Publicado: (2020)

Exposure–safety–efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study
por: Gupta, Neeraj, et al.
Publicado: (2016)

Phase I study of MLN8237—investigational Aurora A kinase inhibitor—in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia
por: Kelly, Kevin R., et al.
Publicado: (2013)

Effect of severe renal impairment on the pharmacokinetics of brigatinib
por: Gupta, Neeraj, et al.
Publicado: (2021)

A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumors
por: Dittrich, Christian, et al.
Publicado: (2014)

Phase 1 dose-escalation, pharmacokinetic, and cerebrospinal fluid distribution study of TAK-285, an investigational inhibitor of EGFR and HER2
por: LoRusso, Patricia, et al.
Publicado: (2013)

A phase I study to assess the mass balance, excretion, and pharmacokinetics of [(14)C]-ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors
por: Gupta, Neeraj, et al.
Publicado: (2017)

Global population pharmacokinetics of the investigational Aurora A kinase inhibitor alisertib in cancer patients: rationale for lower dosage in Asia
por: Zhou, Xiaofei, et al.
Publicado: (2017)

A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors
por: Pant, Shubham, et al.
Publicado: (2013)

Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumors
por: Naing, Aung, et al.
Publicado: (2013)

Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi‐arm phase Ib study
por: Thein, Kyaw Zin, et al.
Publicado: (2021)

A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors
por: Wang-Gillam, Andrea, et al.
Publicado: (2011)

Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors
por: Lockhart, A Craig, et al.
Publicado: (2018)

A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors
por: Adjei, Alex A., et al.
Publicado: (2016)

Phase 1 study to evaluate safety, tolerability and pharmacokinetics of a novel intra-tympanic administered thiosulfate to prevent cisplatin-induced hearing loss in cancer patients
por: Viglietta, Vissia, et al.
Publicado: (2020)

Phase 1b trial of proteasome inhibitor carfilzomib with irinotecan in lung cancer and other irinotecan-sensitive malignancies that have progressed on prior therapy (Onyx IST reference number: CAR-IST-553)
por: Arnold, Susanne M., et al.
Publicado: (2017)

Effects of Itraconazole and Rifampin on the Pharmacokinetics of Mobocertinib (TAK‐788), an Oral Epidermal Growth Factor Receptor Inhibitor, in Healthy Volunteers
por: Zhang, Steven, et al.
Publicado: (2021)

Population Pharmacokinetics and Exposure‐Safety Relationships of Alisertib in Children and Adolescents With Advanced Malignancies
por: Zhou, Xiaofei, et al.
Publicado: (2022)

Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies
por: Smith, David C., et al.
Publicado: (2015)

A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma
por: Bhatia, Shailender, et al.
Publicado: (2016)

A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors
por: Marshall, John, et al.
Publicado: (2012)

ABCG2 impairs the activity of the aurora kinase inhibitor tozasertib but not of alisertib
por: Michaelis, Martin, et al.
Publicado: (2015)

Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors
por: Kummar, Shivaani, et al.
Publicado: (2021)

Cisplatin‐resistant cancer cells are sensitive to Aurora kinase A inhibition by alisertib
por: Wang, Lihong, et al.
Publicado: (2017)

Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry
por: Beumer, J. H., et al.
Publicado: (2007)

Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non–small cell lung cancer
por: Okamoto, Isamu, et al.
Publicado: (2009)

Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies
por: Soto, Elena, et al.
Publicado: (2010)

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics
por: Tortorici, Michael A., et al.
Publicado: (2010)

Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients
por: Fujiwara, Yutaka, et al.
Publicado: (2011)

Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors
por: Okamoto, Isamu, et al.
Publicado: (2010)

Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers
por: Pithavala, Yazdi K., et al.
Publicado: (2010)

Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors
por: Steeghs, Neeltje, et al.
Publicado: (2009)

Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies
por: Deenen, Maarten J., et al.
Publicado: (2011)

Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152)
por: Keizer, Ron J., et al.
Publicado: (2011)

Figitumumab combined with carboplatin and paclitaxel in treatment-naïve Japanese patients with advanced non-small cell lung cancer
por: Goto, Yasushi, et al.
Publicado: (2011)

Eribulin mesylate in patients with refractory cancers: a Phase I study
por: Mukohara, Toru, et al.
Publicado: (2011)

Two-stage model-based clinical trial design to optimize phase I development of novel anticancer agents
por: Zandvliet, Anthe S., et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_akh9ejp05p97ls26okapamlc02